Depreotide Trifluoroacetate
drug drugOn this page
Also known as Neospect
Summary
Depreotide Trifluoroacetate (CHEMBL5315079) is an approved small molecule; indicated across 2 conditions.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 2 conditions
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5315079 |
| Name | Depreotide Trifluoroacetate |
| Type | Small molecule |
| Max phase | 4 |
Also known as: Depreotide trifluoroacetate, Neospect, DEPREOTIDE TRIFLUOROACETATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.